CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Data ReadoutpositiveWATCHMAN FLXPositive
AI Analysis
Summary
The CHAMPION-AF study of Boston Scientific's WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints, demonstrating superior bleeding protection and comparable efficacy to anticoagulant therapy for stroke risk reduction in non-valvular atrial fibrillation patients.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
CHAMPION-AF study met all primary and secondary safety and efficacy endpoints; WATCHMAN FLX demonstrated statistically superior protection from bleeding and similar efficacy to blood thinners
Importance:8/10
Sentiment:
0.85
medical deviceatrial fibrillationstroke preventionclinical trial dataleft atrial appendage closureACC conference
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on March 28, 2026 2:55 PM